UNDERSTANDING RISK STRATIFICATION IN PAH:

PAH Burden of Disease

The Rationale for Evaluation of PAH Severity

ESC/ERS Pulmonary Hypertension Guidelines: Parameters of a Comprehensive Risk Assessment

Comprehensive Prognostic Evaluation and Risk Assessment

PAH Expert Referral Centers

Definition of Patient Status

Classification of WHO Group 1 (PAH)

Components of a Comprehensive Risk Assessment

Suggested Assessment and Timing for Follow-Up of Patients with PAH

Case 1: 45-Year-Old Woman With Idiopathic PAH Before Starting Treatment

Case 1: 45-Year-Old Woman With Idiopathic PAH Before Starting Treatment (cont)

Evidence-Based Treatment Algorithm for Patients With PAH

Case 1: 45-Year-Old Woman With Idiopathic PAH After 4 Months of Treatment With Initial Oral Combination Therapy (PDE5 Inhibitor + ERA)

Case 1: 45-Year-Old Woman With Idiopathic PAH After 4 Months of Treatment With Initial Oral Combination Therapy (PDE5 Inhibitor + ERA) (cont)

Case 1: 45-Year-Old Woman With Idiopathic PAH After 4 Months of Treatment With Initial Oral Combination Therapy (PDE5 Inhibitor + ERA) (cont)

Evidence-Based Treatment Algorithm for Patients With PAH

ESC/ERS Recommendations for Sequential Drug Combination Therapy for PAH

Case 2: 34-Year-Old Man With Idiopathic PAH: Syncope and Breathlessness for 2 Years at Baseline

Case 2: 34-Year-Old Man With Idiopathic PAH: Syncope and Breathlessness for 2 Years at Baseline (cont)

Case 2: 34-Year-Old Man With Idiopathic PAH After 4 Months of Combination Therapy With Intravenous Epoprostenol

Case 2: 34-Year-Old Man With Idiopathic PAH After 4 Months of Combination Therapy With Intravenous Epoprostenol (cont)

Case 3: 64-Year-Old Woman With Scleroderma-Associated PAH at Baseline

Case 3: 64-Year-Old Woman With Scleroderma-Associated PAH at Baseline (cont)

AMBITION: Initial Combination Therapy Improves Patient Outcomes vs Monotherapy in FC II Patients With PAH

Conclusions

Abbreviations

Abbreviations (cont)